There are 3484 resources available
LBA55 - An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer
Presenter: James Black
Session: Proffered Paper session 1 - Basic Science and Translational research
Resources:
Abstract
Slides
Webcast
502MO - Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: A real-life cohort analysis from Veneto Institute of Oncology, Padua (Italy)
Presenter: Giulia Cerretti
Session: Mini oral session: CNS tumours
Resources:
Abstract
Slides
Webcast
Introduction and scientific background
Presenter: Joanna Mangana
Session: What’s the future in melanoma therapy? Novel targets, new drugs, reinvented approaches
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Kohei Shitara
Session: Upper GI cancers: From bench to bedside
Resources:
Slides
Webcast
Where are we in Oncology in relation to developments in digital health, big data, artificial intelligence...? Challenges and opportunities
Presenter: Rudolf Fehrmann
Session: Do we enter a new era of oncology with big data and artificial intelligence?
Resources:
Slides
Webcast
Which factors can cause an E-E gap?
Presenter: Hendrik van Halteren
Session: Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Raffaele Califano
Session: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge
Resources:
Slides
Webcast
Duration of IO treatment
Presenter: Benjamin Besse
Session: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge
Resources:
Slides
Webcast
376O - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
Presenter: Shanu Modi
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
856MO - A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis
Presenter: Dan Zandberg
Session: Mini oral session - Head and neck cancer
Resources:
Abstract
Slides
Webcast